Literature DB >> 1711920

Extracellular matrix proteins and their receptors in the normal, hyperplastic and neoplastic breast.

V E Gould1, G K Koukoulis, I Virtanen.   

Abstract

We studied by immunohistochemistry, the distribution of tenascin (Ten), cellular fibronectin (cFn), laminin and certain pertinent extracellular matrix protein receptors in normal human female breast, variants of fibrocystic disease (FCD), benign tumors, and ductal and lobular carcinomas. Monoclonal antibodies (mAb) to Ten, extradomain A containing cFn (EDAcFn), A and B chains of laminin, and beta-1 (beta-1) and different alpha subunits of intergrins were used. In in-situ ductal and lobular carcinomas, laminin staining had focal gaps, Ten-immunoreactivity displayed periductal or periacinar bands, and cFn showed broad and intense periductal staining; strong reactions for beta-1 and alpha-6 were noted in the basal cytoplasm of non-neoplastic myoepithelial cells while few tumor cells stained weakly. In infiltrating ductal and lobular carcinomas (IDC, ILC), laminin reactivity was weak, uneven or absent around neoplastic clusters whereas stromal staining for Ten and cFn was extensive and strong. In most IDC, moderate beta-1 and alpha-6 staining involved variable subpopulations; one mucinous carcinoma stained strongly and diffusely. In 20-40% of cells in ILC, beta-1 and alpha-6 were localized in delicate, ramified cytoplasmic processes. Indirect immunofluorescence studies with mAbs to other alpha-integrin subunits suggest that in various breast carcinomas only alpha-3 is expressed in tumor cells and that the vessels contained alpha-1 integrin. As compared with the normal breast, FCD and benign tumors, reactivity for Ten and cFn is increased in breast carcinomas while laminin is attenuated and decreased or absent; yet, Ten cannot be regarded as a carcinoma marker since it can be detected in benign tumors, FCD, and even in the normal breast.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1711920     DOI: 10.1016/0922-3371(90)90057-4

Source DB:  PubMed          Journal:  Cell Differ Dev        ISSN: 0922-3371


  22 in total

Review 1.  Integrin α3β1 as a breast cancer target.

Authors:  Sita Subbaram; C Michael Dipersio
Journal:  Expert Opin Ther Targets       Date:  2011-08-13       Impact factor: 6.902

Review 2.  Integrin function in breast carcinoma progression.

Authors:  L M Shaw
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

Review 3.  Integrins: cell adhesives and modulators of cell function.

Authors:  F T Bosman
Journal:  Histochem J       Date:  1993-07

4.  Immunohistochemical localization of integrins in the normal, hyperplastic, and neoplastic breast. Correlations with their functions as receptors and cell adhesion molecules.

Authors:  G K Koukoulis; I Virtanen; M Korhonen; L Laitinen; V Quaranta; V E Gould
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

5.  Enhanced tenascin expression in cervical and vulvar koilocytotic lesions.

Authors:  O Tiitta; T Wahlström; J Paavonen; A Linnala; S Sharma; V E Gould; I Virtanen
Journal:  Am J Pathol       Date:  1992-10       Impact factor: 4.307

6.  Integrin alpha 6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotype in vitro and in vivo.

Authors:  I Rabinovitz; R B Nagle; A E Cress
Journal:  Clin Exp Metastasis       Date:  1995-11       Impact factor: 5.150

7.  The role of the tumor microenvironment in tumor cell intravasation and dissemination.

Authors:  Lucia Borriello; George S Karagiannis; Camille L Duran; Anouchka Coste; Maja H Oktay; David Entenberg; John S Condeelis
Journal:  Eur J Cell Biol       Date:  2020-07-02       Impact factor: 4.492

Review 8.  Breast tumor and stromal cell responses to TGF-β and hypoxia in matrix deposition.

Authors:  Colleen S Curran; Patricia J Keely
Journal:  Matrix Biol       Date:  2012-12-20       Impact factor: 11.583

Review 9.  Hypoxia and the extracellular matrix: drivers of tumour metastasis.

Authors:  Daniele M Gilkes; Gregg L Semenza; Denis Wirtz
Journal:  Nat Rev Cancer       Date:  2014-05-15       Impact factor: 60.716

10.  Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening.

Authors:  E Ruiz-Garcia; V Scott; C Machavoine; J M Bidart; L Lacroix; S Delaloge; F Andre
Journal:  Br J Cancer       Date:  2010-01-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.